StreetAlpha.app
Home › Stocks › PRQR

ProQR Therapeutics N.V. (PRQR)

Healthcare
$1.15
▼ −2.54%
LAST CLOSE · NOV 17

ProQR Therapeutics develops RNA editing medicines for liver and nervous system diseases using its Axiomer platform. It last closed at $1.15 on Nov 17, down 2.54% on the day. The average 12-month price target from 3 analysts is $6.33 (+450.7% from the last close), with a high of $8.00 and a low of $3.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is PRQR in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
EUR 15.9M
−15.9% vs a year ago
Net income
−EUR 42.2M
−265.2% margin
Free cash flow
−EUR 53.8M
−338.3% margin
Operating margin
−273.1%
−EUR 43.4M operating income
Balance sheet
Cash & equivalents
EUR 92.4M
At Dec 31
Debt
EUR 4.9M
At Dec 31
Shareholder equity
EUR 49.4M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: EUR 1.3MEUR 1.3MFY2021FY2022: EUR 3.6MEUR 3.6MFY2022FY2023: EUR 6.5MEUR 6.5MFY2023FY2024: EUR 18.9MEUR 18.9MFY2024FY2025: EUR 15.9MEUR 15.9MFY2025

From PRQR's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 12). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on PRQR in the past 90 days
Average 12-month target
$6.33
▲ 450.7% upside

Based on 3 analysts who set a price target on PRQR in the past 90 days. The average target is $6.33, with a high of $8.00 and a low of $3.00, compared with the last close of $1.15.

Low $3.00Avg $6.33High $8.00
Blue marker: last close $1.15
Highest target$8.00
Average target$6.33
Lowest target$3.00
Latest rating changes
Chardan CapitalMaintained
Oct 1Buy$3
HC Wainwright & Co.Maintained
Oct 1Buy$8
B of A SecuritiesInitiated
Aug 20Buy$8
Evercore ISI GroupMaintained
Jun 29Buy$6
Jones TradingMaintained
Jun 26Buy$10
DateFirmActionRatingPrice target
Oct 1Chardan CapitalMaintainedBuy$3
Oct 1HC Wainwright & Co.MaintainedBuy$8
Aug 20B of A SecuritiesInitiatedBuy$8
Jun 29Evercore ISI GroupMaintainedBuy$6
Jun 26Jones TradingMaintainedBuy$10
Loading…

Technical Analysis

PRQR · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 16% below its 20 day and 34% below its 50 day average. It is 45% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the 52 week low at $1.12, and the nearest resistance the Pivot at $1.16.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.1%/day
Key levels
$2.4952 week high+116.5%
$1.73100 day average+50.4%
$1.67200 day average+45.2%
$1.5450 day average+33.9%
$1.45Swing high (Nov 5)+26.1%
$1.3320 day average+15.7%
$1.20Pivot R1+4.3%
$1.16Pivot+0.9%
$1.15Last close
$1.1252 week low−2.6%
$1.11Pivot S1−3.5%
Indicators
RSI (14)35.42Weak, oversold below 30Neutral
MACD-0.08Below its signal lineBearish
Stochastic26.5Middle of its rangeNeutral
ADX (14)31.0Trending down
Williams %R-92.1Oversold below −80, overbought above −20Oversold
CCI (20)-245.8Oversold below −100, overbought above 100Oversold
Rate of change−16.1%Change over 10 sessionsBearish
ATR (14)$0.10Typical daily range, 9.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PRQR

What happened before

See how PRQR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PRQR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PRQR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PRQR in the last 90 days.

Loading…

See today’s whale options flow across the market →

PRQR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲28 buying vs 24 selling
  • ▼Held by funds -0.6 pts
  • ▲Funds holding +3
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7471+4.2%
In funds' top 1021+100.0%
Held by funds57.1%57.7%−0.6 pts
New / increased11 / 1712 / 25−24.3%
Reduced / sold out16 / 811 / 11+9.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PRQR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRQR is in one of them and how their past PRQR trades turned out.

PRQR in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PRQR in an article yet. Here's the latest on the wider market.

About ProQR Therapeutics N.V.

ProQR is a biotechnology company based in Leiden, Netherlands, that develops RNA editing medicines. It uses its proprietary Axiomer platform, which directs enzymes already present in cells to make precise changes in RNA, to build treatments for diseases of the liver and central nervous system. Its lead candidate is in a Phase 1 trial in healthy volunteers, and its pipeline also covers Rett syndrome, MASH, a liver disease, and cardiovascular disease. The company also works with Eli Lilly on drug targets under a licensing and research collaboration.

Headquarters
Leiden